


Financial Results of the 3rd Quarter for Fiscal Year Ending June 2024

May 15, 2024

(Securities code: 7747 Prime of Tokyo Stock Exchange,
Premier of Nagoya Stock Exchange)

A decorative graphic consisting of multiple overlapping, wavy lines in shades of gray and white, creating a sense of movement and depth across the lower half of the slide.

FYE June 2024 Q3 YTD Main Points - 1

Revenue 80,733 Mil.Yen <Year-on-year +15.7%>

Both Medical and Device Division increased due to exchange rate fluctuation, the recovery and expansion of cases and strong demand, etc. In particular, overseas revenue increased significantly.

Orders for some distributor transactions were particularly concentrated in Q1 due to the convenience of customers, although end-user demand continues to grow quarterly.

- **Medical Division ~Strong performance in all fields: Cardiovascular, Non-cardiovascular, and OEM business~**
 - External environment : Expanded and increased in the number of cases due to disappearing the impact of Covid-19(YoY+5.5%)
Increased revenue due to the exchange rate fluctuation (Yen depreciation)
 - In Cardiovascular field: Increased in all regions, centered on PCI GW and Penetration Catheter
 - In Non-Cardiovascular field: Increased in Peripheral vascular (US, etc.), Abdominal vascular (US/China, etc.)
and Neurovascular (China,etc.)
 - OEM business: Increased due to new orders in US market, etc.
- **Device Division ~ Increased in Medical Components in overseas market ~**
 - External environment : Increased in revenue due to the exchange rate fluctuation(Yen depreciation)
 - In Medical Components business: Increased in Cardiovascular ultrasound catheter components and Cardiovascular inspection components in overseas market
 - In Industrial Components business: Decreased in leisure-related and construction-related transactions although increased in OA equipment
- **Impact of increased revenue due to exchange rate fluctuation (Yen depreciation) +4,384 Mil. Yen**

FYE June 2024 Q3 YTD Main Points - 2

Increased in operating income due to increased in revenue despite increasing SGA

- **Gross profit: 52,508 Mil.Yen < YoY +13.4% >**
 - Increased in gross profit due to increased in revenue
- **Operating income excluding goodwill amortization, etc.: 21,168 Mil. Yen < YoY +18.6% >**
 - Increased in revenue and expenses related to sales promotion activities in domestic and overseas market
 - Increased in R&D expenses (7,988 Mil.Yen) (YoY +892 Mil.Yen, R&D-to-Revenue ratio 9.9 %)
- **Operating income: 19,656 Mil.Yen <YoY +19.7% >**
 - Increased in goodwill amortization, etc. (1,511 Mil. Yen) (YoY +78 Mil. Yen)
- **Ordinary income: 19,621 Mil.Yen <YoY +23.0% >**
 - Non-operating income: Increased in subsidy income (YoY +72 Mil.Yen) and others (YoY +82 Mil.Yen)
 - Non-operating expenses: Decreased in foreign exchange losses (YoY -179 Mil.Yen)
- **Net Income attributable to parent company shareholders: 14,040 Mil.Yen <YoY +17.2% >**
 - Decreased in insurance proceeds on disaster at Cebu factory (YoY -305 Mil.Yen)

Exchange rate (Unit : JPY)	US \$	EURO	CNY	BAHT
FYE June 2024 Q3 YTD	147.13	159.25	20.34	4.15
FYE June 2023 Q3 YTD	137.51	141.95	19.81	3.87

Highlights Year-on-Year

	FYE June 2023 Q3 YTD		FYE June 2024 Q3 YTD				(Reference) At the same exchange rate as the previous year			
	Amount (Mil.Yen)	Ratio (%)	Amount (Mil.Yen)	Ratio (%)	YoY		Amount (Mil.Yen)	Ratio (%)	YoY	
					Changes (Mil.Yen)	Changes (%)			Changes (Mil.Yen)	Changes (%)
Revenue	69,774	100.0	80,733	100.0	+10,958	+15.7	76,348	100.0	+6,573	+9.4
Gross Profit	46,286	66.3	52,508	65.0	+6,221	+13.4	49,627	65.0	+3,341	+7.2
Operating Income excluding goodwill amortization, etc.	17,851	25.6	21,168	26.2	+3,316	+18.6	19,125	25.0	+1,273	+7.1
Operating Income	16,418	23.5	19,656	24.3	+3,238	+19.7	17,703	23.2	+1,285	+7.8
Ordinary Income	15,952	22.9	19,621	24.3	+3,669	+23.0				
Net income attributable to parent company shareholders	11,985	17.2	14,040	17.4	+2,055	+17.2				
EPS (yen)	44.12	–	51.69	–	+7.57	+17.2				
EBITDA	22,868	32.8	26,891	33.3	+4,022	+17.6				

Exchange rate (Unit : JPY)	US \$	EURO	CNY	BAHT
FYE June 2024 Q3 YTD	147.13	159.25	20.34	4.15
FYE June 2023 Q3 YTD	137.51	141.95	19.81	3.87

Revenue by Segment Year-on-year

	FYE June 2023 Q3 YTD		FYE June 2024 Q3 YTD			
	Amount (Mil.Yen)	Ratio (%)	Amount (Mil.Yen)	Ratio (%)	Changes (Mil.Yen)	Changes (%)
Medical	61,075	87.5	71,607	88.7	+10,532	+17.2
Device	8,699	12.5	9,125	11.3	+426	+4.9
Total amount	69,774	100.0	80,733	100.0	+10,958	+15.7

(Reference)


Medical Field	66,421	95.2	77,517	96.0	+11,096	+16.7
Device Field	3,353	4.8	3,215	4.0	- 138	- 4.1

Operating Income by Segment Year-on-year


	FYE June 2023 Q3 YTD		FYE June 2024 Q3 YTD			
	Amount (Mil.Yen)	Operating margin (%)	Amount (Mil.Yen)	Operating margin (%)	Changes (Mil.Yen)	Changes (%)
Operating income excluding goodwill amortization, etc.						
Medical	15,991	26.2	20,543	28.7	+4,551	+28.5
Device	5,053	58.1	4,024	44.1	- 1,028	- 20.3
Erasing & Head Quarters	- 3,193	-	- 3,400	-	- 207	+6.5
Total	17,851	25.6	21,168	26.2	+3,316	+18.6
Operating income						
Medical	14,558	23.8	19,031	26.6	+4,473	+30.7
Device	5,053	58.1	4,024	44.1	- 1,028	- 20.3
Erasing & Head Quarters	- 3,193	-	- 3,400	-	- 207	+6.5
Total	16,418	23.5	19,656	24.3	+3,238	+19.7
(Reference)						
Device Division Segment Revenue	11,273	-	10,231	-	- 1,041	- 9.2

Earnings Performance by Segment


Revenue



Operating income excluding goodwill amortization, etc.




Operating income




Attribution Analysis of Operating Income – 1

(Exchange Rate Fluctuations Included)



Attribution Analysis of Operating Income – 2


(Exchange Rate Fluctuations Excluded)



Situation Per Segment Division

Per Segment by Medical Division (by Geography-1)

(Mil. Yen)



【Revenue (YoY)】

~ Overseas revenue increased significantly due to exchange rate fluctuation, the recovery and expansion of cases and strong demand, etc. ~

- **Japan** : Increased in Non-cardiovascular and OEM business
 - Cardiovascular field : Increased mainly PCI GW
 - Non-cardiovascular field : Increased in Gastrointestinal/Peripheral vascular products and second sales of the surgery support robot "ANSUR"
 - OEM Business : Increased in Cardiovascular and Gastrointestinal field in OEM business
- **Overseas** : Increased in all regions due to exchange rate fluctuation, recovering and expanding cases and strong demand
 - **US**
 - Cardiovascular field : Increased in mainly in PCI GW/Penetration Catheter
 - Non-cardiovascular field : Increased in Peripheral vascular products (New product "CROSSLEAD", "CROSSWALK" effect) , increased in Abdominal vascular products.
 - OEM Business: Increased in new OEM orders of Cardiovascular field
 - **Europe**
 - Cardiovascular field : Increased in PCI GW/Penetration Catheter, concentrated orders for eastern Europe centered on Q1
 - Non-cardiovascular field : Slightly increased mainly in Neurovascular products
 - **China**
 - Cardiovascular field : Strong sales of PCI GW, Penetration Catheter and Balloon Catheter (purchased products)
 - Non-cardiovascular field : Increased mainly in all fields such as Abdominal vascular, Neurovascular and Peripheral vascular products
 - **Other**
 - Cardiovascular field : Strong sales of PCI GW/Penetration Catheter mainly in Asia
 - Non-cardiovascular field : Strong sales in all fields such as Abdominal, Peripheral and Neurovascular products mainly in Asia

【Operating Income】


Operating income increased in proportion to revenue

Per Segment by Medical Division (by Geography-2)

(Mil. Yen)		FYE June 2023 Q3 YTD	FYE June 2024 Q3 YTD	YoY	
				Changes	Changes (%)
Exchange rate (Yen)	USD	137.51	147.13	+9.62	+7.0
	EURO	141.95	159.25	+17.30	+12.2
	CNY	19.81	20.34	+0.53	+2.7
Total Revenue		61,075	71,607	+10,532	+17.2
Japan		10,120	10,903	+783	+7.7
Overseas		50,955	60,703	+9,748	+19.1
US		13,321	15,773	+2,452	+18.4
Europe		13,972	16,750	+2,778	+19.9
China		15,236	17,589	+2,353	+15.4
Other		8,425	10,589	+2,163	+25.7
Operating income		14,558	19,031	+4,473	+30.7

Per Segment by Medical Division (by Treatment-1)

【Revenue (YoY)】



Cardiovascular

- Japan : Increased mainly PCI GW
- Overseas : Increased due to exchange rate fluctuation, recovering and expanding the number of cases and strong demand
 - US: Increased mainly PCI GW / Penetration Catheter
 - Europe : Increased PCI GW/Penetration Catheter, concentrated orders for eastern Europe centered on Q1
 - China : Strong sales of PCI GW, Penetration Catheter and Balloon Catheter (purchased products)
 - Other : Strong sales of PCI GW/Penetration Catheter mainly in Asia

Non-Cardiovascular

- Japan : Increased in Gastrointestinal/Peripheral vascular products
Second sales of surgery support robot "ANSUR"
- Overseas : Increased in US, China and Asia
 - US : Increased in Peripheral (New product "CROSSLEAD", "CROSSWALK" effect) /Abdominal vascular products
 - Europe :Slightly increased mainly in Neurovascular products
 - China : Increased in all fields such as Abdominal vascular, Peripheral vascular and Neurovascular products
 - Other : Strong sales in all fields such as Abdominal vascular, Peripheral vascular and Neurovascular products mainly in Asia


OEM

- Japan : Strong sales for Cardiovascular and Gastrointestinal fields
- Overseas : Increased in US (New orders of Cardiovascular)and Asia, etc.

Per Segment by Medical Division (by Treatment-2)

(Mil. Yen)		FYE June 2023 Q3 YTD	FYE June 2024 Q3 YTD	YoY	
				Changes	Changes(%)
Exchange rate (Yen)	USD	137.51	147.13	+9.62	+7.0
	EURO	141.95	159.25	+17.30	+12.2
	CNY	19.81	20.34	+0.53	+2.7
Total Revenue		61,075	71,607	+10,532	+17.2
	Japan	10,120	10,903	+783	+7.7
	Overseas	50,955	60,703	+9,748	+19.1
Cardiovascular		46,369	54,014	+7,644	+16.5
	Japan	6,095	6,259	+163	+2.7
	Overseas	40,274	47,754	+7,480	+18.6
Non-Cardiovascular		9,278	11,573	+2,294	+24.7
	Japan	2,861	3,291	+430	+15.0
	Overseas	6,417	8,281	+1,864	+29.1
OEM		5,427	6,019	+592	+10.9
	Japan	1,163	1,352	+189	+16.3
	Overseas	4,263	4,667	+403	+9.5

Per Segment by Device Division-1



【Revenue (YoY)】

Increased medical components in overseas market

Medical Component

- Japan : Increased in components sales for endoscopy
- Overseas : Increased in Cardiovascular ultrasound catheter components and Cardiovascular inspection catheter components

Industrial Component

- Japan : Shrunk in construction related transactions
- Overseas : Decreased in leisure-related transactions although increased in OA equipment-related transactions

【Operating income】

Decreased due to decreasing intersegment transactions although external revenue increased

Per Segment by Device Division-2

(Mil. Yen)		FYE June 2023 Q3 YTD	FYE June 2024 Q3 YTD	YoY	
				Changes	Changes (%)
Exchange rate (Yen)	USD	137.51	147.13	+9.62	+7.0
Total Revenue		8,699	9,125	+426	+4.9
	Japan	2,127	2,096	- 31	- 1.5
	Overseas	6,572	7,029	+457	+7.0
Medical Components		5,345	5,910	+564	+10.6
	Japan	743	818	+74	+10.0
	Overseas	4,602	5,092	+489	+10.6
Industrial Components		3,353	3,215	- 138	- 4.1
	Japan	1,383	1,277	- 105	- 7.7
	Overseas	1,970	1,937	- 32	- 1.7
Operating income		5,053	4,024	- 1,028	- 20.3
(Reference) Segment Revenue		11,273	10,231	- 1,041	- 9.2


Reference: P/L

	FYE June 2023 Q3 YTD		FYE June 2024 Q3 YTD			
	Amount (Mil. Yen)	Ratio (%)	Amount (Mil. Yen)	Ratio (%)	Changes (Mil. Yen)	Main comparison factors
Revenue	69,774	100.0	80,733	100.0	+10,958	•Progressed well mainly overseas revenue
Cost of sales	23,488	33.7	28,224	35.0	+4,736	
Gross profit	46,286	66.3	52,508	65.0	+6,221	•Increased in proportion to revenue
SGA	29,868	42.8	32,851	40.7	+2,983	•Increased in expenses related to sales and R&D
Operating income excl. goodwill amortization	17,851	25.6	21,168	26.2	+3,316	
Operating income	16,418	23.5	19,656	24.3	+3,238	
Non-operating income	163	0.2	376	0.5	+212	•Increased in subsidy income, etc.
Non-operating expense	629	0.9	411	0.5	- 218	•Decreased in foreign exchange losses
Ordinary income	15,952	22.9	19,621	24.3	+3,669	
Extraordinary income	305	0.4	4	0.0	- 301	•Occurrence insurance proceeds on disaster at Cebu factory in the previous quarter
Extraordinary loss	187	0.3	199	0.2	+12	
Net income attributable to parent company shareholders	11,985	17.2	14,040	17.4	+2,055	
Quarterly Comprehensive income	12,094	17.3	16,545	20.5	+4,451	

Reference: B/S

		FYE June 2023 Results		FYE June 2024 Q3			
		Amount (Mil. Yen)	Ratio (%)	Amount (Mil. Yen)	Ratio (%)	Changes (Mil. Yen)	Main comparison factors
Assets	Current assets	90,261	52.3	93,833	52.5	+3,571	Notes and accounts receivable +3,450
	Fixed assets	82,383	47.7	85,040	47.5	+2,657	Buildings and structures + 2,039
Total assets		172,644	100.0	178,874	100.0	+6,229	
Liabilities	Current liabilities	26,316	15.2	22,608	12.6	- 3,707	Notes and accounts payable - 607 Shot-term borrowings - 3,185
	Fixed liabilities	12,028	7.0	10,640	5.9	- 1,387	Long-term borrowings - 2,701 Others + 1,060
Total liabilities		38,344	22.2	33,248	18.6	- 5,095	
Total net assets		134,300	77.8	145,625	81.4	+11,325	Retained earnings +10,107 Foreign currency translation adjustment + 2,211 Non-controlling interests - 1,261
Total liabilities & net assets		172,644	100.0	178,874	100.0	+6,229	

Reference: C/F



Caution Regarding Information Presented

All forward looking statements contained herein, including revenue forecasts, outlooks, and strategic plans, are based on the best currently available data; however, risk and uncertainty are involved in these statements.

Please note that actual results may differ greatly from plans presented here.

[IR contact]

Asahi Intecc Co., Ltd.
corporate strategic office

TEL 0561-48-5551

URL <http://www.asahi-intecc.co.jp/en/>